Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the provided transcript. CAPEX investments are primarily funded through internal accruals and careful investment decisions. Kuldeep Jain mentioned being open to investing in new CAPEX only if there is a strong business case. No explicit plans or guidance about raising fresh capital through debt or equity were disclosed during the call. The company is focusing on utilizing existing capacities and strategic debottlenecking to enhance growth and returns.

Any current/future capex/capital investment/strategic investment?

FY24 CAPEX was about Rs.230 crores, with approximately Rs.140 crores spent on the animal health segment (page 16). The animal health plant has started operations and no immediate further CAPEX is planned unless future debottlenecking or additional reactors are needed (page 16). For FY25, estimated CAPEX is around Rs.100-120 crores, mainly for debottlenecking and infrastructure upgrades (page 9). Beyond FY25, the company is open to CAPEX investments provided there is a strong business case (page 9). Most CAPEX in recent years focused 55-60% on growth initiatives, with commercial supply starting

Future growth expectations in sales/revenue/volumes?

Hikal targets a medium-term sales growth of 12-15% annually, driven by the pharmaceutical and crop protection segments. The company expects the animal health business to contribute significantly, aiming for commercial-scale production and revenue ramp-up over 2-2.5 years post-validation. Crop protection business anticipates recovery towards the end of FY25, after destocking and inventory normalization. The CDMO business maintains a strong pipeline with consistent new product launches, expected to increase the CDMO share back to historical levels. New multi-purpose facility and CAPEX investment

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal Limited expects steady top-line growth of 12-15% over the next 3-5 years, driven by pharma and crop protection segments. Pharma business shows a positive trend with stabilized raw material prices and improved margin profile; EBIT margin for Q4 FY24 was 15.9%. EBITDA margin improved by 220 basis points YoY to 18.4% in Q4 FY24, with strong sequential revenue growth of 15%. Full capacity utilization and new growth CAPEX ramp-up over the next 2-3 years is expected to drive margins above 20% and ROCE into the high teens. Animal health segment expected to contribute commercial quantiti

Current/ Expected Orderbook/ Pending Orders?

The CDMO business maintains a healthy pipeline of enquiries from both current and prospective clients. Numerous projects in the crop protection segment are in the advanced stage of discussion with existing innovator customers and new clients, expected to come onstream in the next few years. There is strong interest from global innovators to move supply chains out of China, leading to new project opportunities in India with new chemistries and technologies. The company is focused on molecules with better margin profiles to strengthen its position and drive mid-to-long-term growth. Valid

IN US

Sale is live|00:00:00left today

Hikal LtdQ1 FY24Pharmaceuticals & Biotechnology

Hikal Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Hikal targets a medium-term sales growth of 12-15% annually, driven by the pharmaceutical and crop protection segments.
→The company expects the animal health business to contribute significantly, aiming for commercial-scale production and revenue ramp-up over 2-2.5 years post-validation.
→Crop protection business anticipates recovery towards the end of FY25, after destocking and inventory normalization.
→The CDMO business maintains a strong pipeline with consistent new product launches, expected to increase the CDMO share back to historical levels.
→New multi-purpose facility and CAPEX investments (about Rs. 200+ crores) are expected to support volume growth and capacity utilization improvements starting FY25-26.
→Growth in legacy APIs and food ingredients pipeline (expected peak around 2026) will add to revenue.
→Overall, the company is optimistic about the medium to long-term growth potential due to supply chain shifts from China and demand recovery.

Margin guidance

Category 1

→Hikal Limited expects steady top-line growth of 12-15% over the next 3-5 years, driven by pharma and crop protection segments.
→Pharma business shows a positive trend with stabilized raw material prices and improved margin profile; EBIT margin for Q4 FY24 was 15.9%.
→EBITDA margin improved by 220 basis points YoY to 18.4% in Q4 FY24, with strong sequential revenue growth of 15%.
→Full capacity utilization and new growth CAPEX ramp-up over the next 2-3 years is expected to drive margins above 20% and ROCE into the high teens.
→Animal health segment expected to contribute commercial quantities in 14-18 months post-validation, potentially adding Rs.300-400 crores revenue over 4-5 years.
→Crop protection business is poised for medium to long-term recovery post current destocking and price pressures, with normalization expected by end of FY25.
→Focus on global innovators and CDMO segment with better margin profiles to strengthen operating profits.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity in the provided transcript.
→CAPEX investments are primarily funded through internal accruals and careful investment decisions.
→Kuldeep Jain mentioned being open to investing in new CAPEX only if there is a strong business case.
→No explicit plans or guidance about raising fresh capital through debt or equity were disclosed during the call.
→The company is focusing on utilizing existing capacities and strategic debottlenecking to enhance growth and returns.

Order book

→The CDMO business maintains a healthy pipeline of enquiries from both current and prospective clients.
→Numerous projects in the crop protection segment are in the advanced stage of discussion with existing innovator customers and new clients, expected to come onstream in the next few years.
→There is strong interest from global innovators to move supply chains out of China, leading to new project opportunities in India with new chemistries and technologies.
→The company is focused on molecules with better margin profiles to strengthen its position and drive mid-to-long-term growth.
→Validation batches for animal health products are ongoing, with commercial orders expected to start about 14 to 18 months post-validation.
→Overall, there is a strong orderbook and encouraging enquiries indicating a positive outlook for upcoming contract wins and volume ramp-ups.

Capex plans

Yes

→FY24 CAPEX was about Rs.230 crores, with approximately Rs.140 crores spent on the animal health segment (page 16).
→The animal health plant has started operations and no immediate further CAPEX is planned unless future debottlenecking or additional reactors are needed (page 16).
→For FY25, estimated CAPEX is around Rs.100-120 crores, mainly for debottlenecking and infrastructure upgrades (page 9).
→Beyond FY25, the company is open to CAPEX investments provided there is a strong business case (page 9).
→Most CAPEX in recent years focused 55-60% on growth initiatives, with commercial supply starting from H2 FY26 (page 9).
→Debottlenecking opportunities with high short-term ROI exist in food ingredients, pharma, and crop protection segments (page 9).
→No major new CAPEX is expected next year unless big new contracts or business requirements arise (page 9).

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio